Respiro Diagnostics is developing a breath-based diagnostic platform that analyses DNA, RNA and proteins collected from exhaled breath to support the detection and molecular profiling of lung cancer and other respiratory diseases.
Respiro Diagnostics, a UK-based startup developing breath-based diagnostics for lung
diseases, has raised £1 million in a pre-seed funding round led by Zinc Venture Capital and SFC Capital. The round also included participation from Amadeus
Capital Partners, the Conception X Angel Syndicate, KQ Labs through the Francis
Crick Institute, strategic angel investors and Innovate UK.
Founded by Alison Quinn and Dr Theo Issitt, Respiro is developing a non-invasive liquid biopsy
Catching Cancer Earlier, One Breath at a Time: SpotitEarly Partners with HITLAB to Accelerate Its U.S. Launch
WHEAT RIDGE, CO / ACCESS Newswire / June 15, 2026 / Lifeloc Technologies, Inc. (OTC PINK:LCTC), a global leader in the…
Co-Diagnostics completed clinical and analytical studies for its PCR Flu A/B & RSV test and plans FDA 510(k) and CLIA waiver…
Using a portable sensor, the technology analyzes exhaled biomarkers to detect lung conditions without a lab test or chest x-ray.
bioAffinity Technologies Announces Closing of $3.2 Million OfferingbioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW),a…
Sole lead manager Ord Minnett was offering new shares at 40¢ a pop on Wednesday, representing a 13 per cent discount to the last…
